Selected research
Market Structure
Global Viibryd (Vilazodone) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Viibryd (Vilazodone) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Viibryd (Vilazodone) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Viibryd (Vilazodone) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Viibryd (Vilazodone) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Viibryd (Vilazodone) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Viibryd (Vilazodone) include Clinical Data, Inc., Allergan plc (AbbVie Inc.) and Actavis Generics (Teva), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Viibryd (Vilazodone) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Viibryd (Vilazodone) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Viibryd (Vilazodone) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Viibryd (Vilazodone) market size, projected growth trends, production technologies, key applications, and end-use industries.
Viibryd (Vilazodone) Segment by Company
Clinical Data, Inc.
Allergan plc (AbbVie Inc.)
Actavis Generics (Teva)
Viibryd (Vilazodone) Segment by Type
10 mg
20 mg
40 mg
Viibryd (Vilazodone) Segment by Application
Major Depression
Anxiety
Others
Viibryd (Vilazodone) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viibryd (Vilazodone) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Viibryd (Vilazodone) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viibryd (Vilazodone).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Viibryd (Vilazodone) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viibryd (Vilazodone) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Viibryd (Vilazodone) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Viibryd (Vilazodone) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 10 mg
- 20 mg
- 40 mg
Applications
- Major Depression
- Anxiety
- Others
Companies covered
- Clinical Data, Inc.
- Allergan plc (AbbVie Inc.)
- Actavis Generics (Teva)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Viibryd (Vilazodone) Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Viibryd (Vilazodone) Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Viibryd (Vilazodone) Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Viibryd (Vilazodone) Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Viibryd (Vilazodone) Market Dynamics
- 2.1 Viibryd (Vilazodone) Industry Trends
- 2.2 Viibryd (Vilazodone) Industry Drivers
- 2.3 Viibryd (Vilazodone) Industry Opportunities and Challenges
- 2.4 Viibryd (Vilazodone) Industry Restraints
3 Viibryd (Vilazodone) Market by Manufacturers
- 3.1 Global Viibryd (Vilazodone) Revenue by Manufacturers (2021-2026)
- 3.2 Global Viibryd (Vilazodone) Sales by Manufacturers (2021-2026)
- 3.3 Global Viibryd (Vilazodone) Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Viibryd (Vilazodone) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Viibryd (Vilazodone) Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Viibryd (Vilazodone) Manufacturers, Product Type & Application
- 3.7 Global Viibryd (Vilazodone) Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Viibryd (Vilazodone) Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Viibryd (Vilazodone) Players Market Share by Revenue in 2025
- 3.8.3 2025 Viibryd (Vilazodone) Tier 1, Tier 2, and Tier 3
4 Viibryd (Vilazodone) Market by Type
- 4.1 Viibryd (Vilazodone) Type Introduction
- 4.1.1 10 mg
- 4.1.2 20 mg
- 4.1.3 40 mg
- 4.2 Global Viibryd (Vilazodone) Sales by Type
- 4.2.1 Global Viibryd (Vilazodone) Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Viibryd (Vilazodone) Sales by Type (2021-2032)
- 4.2.3 Global Viibryd (Vilazodone) Sales Market Share by Type (2021-2032)
- 4.3 Global Viibryd (Vilazodone) Revenue by Type
- 4.3.1 Global Viibryd (Vilazodone) Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Viibryd (Vilazodone) Revenue by Type (2021-2032)
- 4.3.3 Global Viibryd (Vilazodone) Revenue Market Share by Type (2021-2032)
5 Viibryd (Vilazodone) Market by Application
- 5.1 Viibryd (Vilazodone) Application Introduction
- 5.1.1 Major Depression
- 5.1.2 Anxiety
- 5.1.3 Others
- 5.2 Global Viibryd (Vilazodone) Sales by Application
- 5.2.1 Global Viibryd (Vilazodone) Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Viibryd (Vilazodone) Sales by Application (2021-2032)
- 5.2.3 Global Viibryd (Vilazodone) Sales Market Share by Application (2021-2032)
- 5.3 Global Viibryd (Vilazodone) Revenue by Application
- 5.3.1 Global Viibryd (Vilazodone) Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Viibryd (Vilazodone) Revenue by Application (2021-2032)
- 5.3.3 Global Viibryd (Vilazodone) Revenue Market Share by Application (2021-2032)
6 Global Viibryd (Vilazodone) Sales by Region
- 6.1 Global Viibryd (Vilazodone) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Viibryd (Vilazodone) Sales by Region (2021-2032)
- 6.2.1 Global Viibryd (Vilazodone) Sales by Region (2021-2026)
- 6.2.2 Global Viibryd (Vilazodone) Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Viibryd (Vilazodone) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Viibryd (Vilazodone) Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Viibryd (Vilazodone) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Viibryd (Vilazodone) Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Viibryd (Vilazodone) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Viibryd (Vilazodone) Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Viibryd (Vilazodone) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Viibryd (Vilazodone) Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Viibryd (Vilazodone) Revenue by Region
- 7.1 Global Viibryd (Vilazodone) Revenue by Region
- 7.1.1 Global Viibryd (Vilazodone) Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Viibryd (Vilazodone) Revenue by Region (2021-2026)
- 7.1.3 Global Viibryd (Vilazodone) Revenue by Region (2027-2032)
- 7.1.4 Global Viibryd (Vilazodone) Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Viibryd (Vilazodone) Revenue (2021-2032)
- 7.2.2 North America Viibryd (Vilazodone) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Viibryd (Vilazodone) Revenue (2021-2032)
- 7.3.2 Europe Viibryd (Vilazodone) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Viibryd (Vilazodone) Revenue (2021-2032)
- 7.4.2 Asia-Pacific Viibryd (Vilazodone) Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Viibryd (Vilazodone) Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Viibryd (Vilazodone) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Clinical Data, Inc.
- 8.1.1 Clinical Data, Inc. Company Information
- 8.1.2 Clinical Data, Inc. Business Overview
- 8.1.3 Clinical Data, Inc. Viibryd (Vilazodone) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Clinical Data, Inc. Viibryd (Vilazodone) Product Portfolio
- 8.1.5 Clinical Data, Inc. Recent Developments
- 8.2 Allergan plc (AbbVie Inc.)
- 8.2.1 Allergan plc (AbbVie Inc.) Company Information
- 8.2.2 Allergan plc (AbbVie Inc.) Business Overview
- 8.2.3 Allergan plc (AbbVie Inc.) Viibryd (Vilazodone) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Allergan plc (AbbVie Inc.) Viibryd (Vilazodone) Product Portfolio
- 8.2.5 Allergan plc (AbbVie Inc.) Recent Developments
- 8.3 Actavis Generics (Teva)
- 8.3.1 Actavis Generics (Teva) Company Information
- 8.3.2 Actavis Generics (Teva) Business Overview
- 8.3.3 Actavis Generics (Teva) Viibryd (Vilazodone) Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Actavis Generics (Teva) Viibryd (Vilazodone) Product Portfolio
- 8.3.5 Actavis Generics (Teva) Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Viibryd (Vilazodone) Value Chain Analysis
- 9.1.1 Viibryd (Vilazodone) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Viibryd (Vilazodone) Production Mode & Process
- 9.2 Viibryd (Vilazodone) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Viibryd (Vilazodone) Distributors
- 9.2.3 Viibryd (Vilazodone) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst